Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Dr. Postow Discusses Combination Therapy for Melanoma

Michael A. Postow, MD
Published: Tuesday, Dec 05, 2017



Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination therapy for patients with melanoma.

There are many new combination therapies for patients with melanoma, says Postow. In the BRAF-mutant population, there are combinations of BRAF and MEK inhibitors with immunotherapy drugs that are moving into phase III trials.

Immunotherapy combinations are also moving forward in clinical trials as well, adds Postow. Namely, combinations of IDO blockers and PD-1 agents.
 
SELECTED
LANGUAGE


Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination therapy for patients with melanoma.

There are many new combination therapies for patients with melanoma, says Postow. In the BRAF-mutant population, there are combinations of BRAF and MEK inhibitors with immunotherapy drugs that are moving into phase III trials.

Immunotherapy combinations are also moving forward in clinical trials as well, adds Postow. Namely, combinations of IDO blockers and PD-1 agents.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x